{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:29:27Z","timestamp":1776486567848,"version":"3.51.2"},"reference-count":16,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"DOI":"10.1182\/bloodadvances.2022009366","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T21:03:51Z","timestamp":1685567031000},"page":"3378-3381","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["<i>BTK<\/i> mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-782X","authenticated-orcid":false,"given":"Ross A.","family":"Jackson","sequence":"first","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-1635","authenticated-orcid":false,"given":"Robert G.","family":"Britton","sequence":"additional","affiliation":[{"name":"2Department of Genetics and Genome Biology, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"},{"name":"3Department of Chemistry, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Jayne","sequence":"additional","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-3383","authenticated-orcid":false,"given":"Susann","family":"Lehmann","sequence":"additional","affiliation":[{"name":"4Institute for Precision Health, Leicester Drug Discovery and Diagnostics, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5582-4492","authenticated-orcid":false,"given":"Caroline M.","family":"Cowley","sequence":"additional","affiliation":[{"name":"5Department of Genetics and Genome Biology, Leicester Molecular Diagnostics, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-3533","authenticated-orcid":false,"given":"Christopher S.","family":"Trethewey","sequence":"additional","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria M.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-4023","authenticated-orcid":false,"given":"Ralf","family":"Schmid","sequence":"additional","affiliation":[{"name":"6Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Fegan","sequence":"additional","affiliation":[{"name":"7University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-711X","authenticated-orcid":false,"given":"Harriet S.","family":"Walter","sequence":"additional","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-2236","authenticated-orcid":false,"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"1Department of Genetics and Genome Biology, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"20","key":"2023072113403257400_bib1","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023072113403257400_bib2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2023072113403257400_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023072113403257400_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2023072113403257400_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"2023072113403257400_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"Gango","year":"2020","journal-title":"Int J Cancer"},{"issue":"24","key":"2023072113403257400_bib7","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023072113403257400_bib8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023072113403257400_bib9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2023072113403257400_bib10","article-title":"Resistance to acalabrutinib in\u00a0CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023072113403257400_bib11","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023072113403257400_bib12","first-page":"15","article-title":"High clonal complexity of resistance mechanisms occurring at progression after single-agent targeted therapy strategies in chronic lymphocytic leukemia","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"736","key":"2023072113403257400_bib13","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"issue":"10277","key":"2023072113403257400_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2023072113403257400_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A\u00a0phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2023072113403257400_bib16","doi-asserted-by":"crossref","first-page":"e127566","DOI":"10.1172\/jci.insight.127566","article-title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity","volume":"4","author":"Wang","year":"2019","journal-title":"JCI Insight"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3378\/2065340\/blooda_adv-2022-009366-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3378\/2065340\/blooda_adv-2022-009366-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T13:40:46Z","timestamp":1689946846000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3378\/496127\/BTK-mutations-in-patients-with-chronic-lymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":16,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009366","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}